AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 03/01/22

Amneal Pharmaceuticals (NYSE:AMRX) said the U.S. FDA approved its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen. The product will be marketed under the proprietary name RELEUKOTM. RELEUKOTM was developed in collaboration with Kashiv Biosciences in ...

- First of three Amneal biosimilars expected for U.S. approval and launch in 2022 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License A...

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q4 earnings results on Wednesday, Mar. 2, before market open. The consensus EPS estimate is $0.20 (+42.9% Y/Y) and the consensus revenue estimate is $533.41M (+4.6% Y/Y). Over the last 2 years, AMRX has beaten EPS estimates 100% of t...

The U.S. Food and Drug Administration (FDA) approved  four generic injectables products from Amneal Pharmaceuticals (NYSE:AMRX). Dexamethasone sodium phosphate injection, USP 10 mg/mL, azacitidine 100 mg, carboprost tromethamine injection, USP 250 mcg/mL, and atropine sulfate inject...

- Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the approval of four generic injectables products. Dexamethasone so...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced today that the Company will release its fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022, prior to market open. The Company will host a conference call and live webcast with ...

- Expands Amneal’s Neurology Presence into Spasticity Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and Saol Therapeutics, a private specialty pharmaceutical company (“Saol”), today announced a definitive agreement under which Amneal...

We will revisit generic and specialty drug maker Amneal Pharmaceuticals for the first time since early this year. The company is expanding its higher margin specialty drug business, just saw a large insider purchase by its CEO, and announced an acquisition. A full investment analy...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 40 th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 11:15 AM Eastern Time. A liv...

Whether you’re looking for a Santa Claus Rally or trying to find some tax-loss harvesting opportunities, omicron fears have slapped the market in the face to start the short holiday week. Over the weekend, concerns began to grow thanks to commentary from the scientific community. The...